Genentech struck a multi‑year collaboration with Caris Life Sciences to accelerate discovery of drug targets and biomarkers across solid tumors, a deal valued at up to $1.1 billion including upfront and milestone payments. Caris is eligible for near‑term payments and research support to leverage its molecular profiling and biomarker datasets to inform Genentech’s oncology pipeline. The agreement pairs Genentech’s development engine with Caris’s tumor profiling capabilities to fast‑track translational hypotheses, patient selection strategies, and target validation. The structure includes initial payments and milestone incentives tied to successful target nomination and program advancement. For the industry, the pact underscores major pharma’s appetite to outsource early target discovery to precision‑medicine specialists and to use real‑world molecular datasets to derisk translational programs and speed clinical candidate selection.